[
  {
    "title": "2 Beaten-Down Stocks to Buy on the Dip",
    "published": 1742673840,
    "posting_price": 505.0,
    "close_price": 511.73999023,
    "percent_change": 1.33465153
  },
  {
    "title": "Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?",
    "published": 1742571030,
    "posting_price": 505.42001343,
    "close_price": 503.20001221,
    "percent_change": -0.43923888
  },
  {
    "title": "As The Biotech Sector Remains Strong, Vertex Stock Trades Near Buy Point",
    "published": 1742558455,
    "posting_price": 505.42001343,
    "close_price": 503.20001221,
    "percent_change": -0.43923888
  },
  {
    "title": "Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
    "published": 1742461970,
    "posting_price": 509.98999023,
    "close_price": 510.17999268,
    "percent_change": 0.03725611
  },
  {
    "title": "CRISPR Therapeutics AG (CRSP): A Bull Case Theory",
    "published": 1742391707,
    "posting_price": 512.01000977,
    "close_price": 512.52001953,
    "percent_change": 0.09960933
  },
  {
    "title": "Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?",
    "published": 1742222820,
    "posting_price": 505.20001221,
    "close_price": 513.76000977,
    "percent_change": 1.69437794
  },
  {
    "title": "3 Unstoppable Stocks You Can Buy Now Without Any Hesitation",
    "published": 1742208420,
    "posting_price": 505.20001221,
    "close_price": 513.76000977,
    "percent_change": 1.69437794
  },
  {
    "title": "Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report?",
    "published": 1741966234,
    "posting_price": 507.0,
    "close_price": 504.76998901,
    "percent_change": -0.43984438
  },
  {
    "title": "3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now",
    "published": 1741945860,
    "posting_price": 507.0,
    "close_price": 504.76998901,
    "percent_change": -0.43984438
  },
  {
    "title": "Vertex Pharma scientist talks about the long road to developing non-addictive painkillers",
    "published": 1713196841,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock",
    "published": 1713186900,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know",
    "published": 1713186250,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "TD Cowen says sickle cell therapies may get higher CMS payments",
    "published": 1713153180,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study",
    "published": 1713143160,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "3 Magnificent Stocks That Could Double or More by 2030",
    "published": 1713012420,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Could This Stock Be the Next Biotech Buyout?",
    "published": 1713000540,
    "posting_price": 400.0,
    "close_price": 397.35998535,
    "percent_change": -0.66000366
  },
  {
    "title": "Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex",
    "published": 1712939760,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Health Care Roundup: Market Talk",
    "published": 1712933700,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Buy Rating Affirmed: Vertex Pharmaceuticals\u2019 Strategic Acquisition and Market Positioning Promise Growth",
    "published": 1712925660,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)",
    "published": 1712925660,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Analyst Maintains \u2018Sell\u2019 Rating on Vertex Pharmaceuticals Amid Skepticism Over Alpine Acquisition and Early-Stage Data",
    "published": 1712925420,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals",
    "published": 1712923440,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals\u2019 Hold Rating: Balancing Cystic Fibrosis Success with Uncertain Growth from New Acquisition",
    "published": 1712915760,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse",
    "published": 1712898534,
    "posting_price": 396.57000732,
    "close_price": 396.54998779,
    "percent_change": -0.00504817
  },
  {
    "title": "Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal",
    "published": 1712867342,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement",
    "published": 1712854116,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "NEW YORK MARKET CLOSE: Soft PPI spurs tech stocks ahead of earnings",
    "published": 1712852280,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences",
    "published": 1712849028,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street  Says.",
    "published": 1712847780,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It",
    "published": 1712846205,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today",
    "published": 1712843276,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer",
    "published": 1712842766,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals: Buy, Sell, or Hold?",
    "published": 1712841300,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024",
    "published": 1712837640,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "US STOCKS-Futures slip as rate-cut hopes ebb",
    "published": 1712830642,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock",
    "published": 1712830140,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Analyst thinks this drugmaker could be next after Alpine's $4.9B acquisition",
    "published": 1712829000,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Apple Spyware Warning: What to Know About \u2018Mercenary Spyware Attack\u2019 Alerts",
    "published": 1712828640,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'",
    "published": 1712828422,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals price target raised by $5 at H.C. Wainwright, here's why",
    "published": 1712821380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharma upgraded at Evercore on Alpine Immune deal",
    "published": 1712821260,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Immune Sciences just downgraded at Leerink, here's why",
    "published": 1712818140,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler",
    "published": 1712816820,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stifel Nicolaus Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)",
    "published": 1712816760,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Futures slip as rate-cut hopes ebb",
    "published": 1712816242,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Buy Rating Justified by Vertex Pharmaceuticals\u2019 Strategic Acquisitions and Promising Drug Pipeline",
    "published": 1712815020,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Evercore ISI upgrades Vertex Pharmaceuticals (VRTX) to a Buy",
    "published": 1712813880,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Evercore expects Vera Therapeutics to trade up on Alpine acquisition news",
    "published": 1712813700,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharmaceuticals just upgraded at Evercore ISI, here's why",
    "published": 1712813220,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Drugmakers look to alternative suppliers after draft U.S. legislation, FT says",
    "published": 1712812980,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options",
    "published": 1712812755,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Strategic Acquisition and Pipeline Expansion Justify Buy Rating for Vertex Pharmaceuticals",
    "published": 1712811480,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)",
    "published": 1712809380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Buy Rating Affirmed for Vertex Pharmaceuticals Post Alpine Therapeutics Acquisition",
    "published": 1712809020,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Alpine Immune downgraded to Sector Perform from Outperform at RBC Capital",
    "published": 1712808660,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal",
    "published": 1712807760,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Immune Deal",
    "published": 1712807580,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "M&A: Vertex Bolsters Drug Pipeline with Alpine Immune Deal",
    "published": 1712807280,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Stock market today: Wall Street rebounds following its slide as Big Tech takes the reins again",
    "published": 1712803980,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact",
    "published": 1712800380,
    "posting_price": 404.29998779,
    "close_price": 400.23001099,
    "percent_change": -1.0066725
  },
  {
    "title": "Vertex Pharma\u2019s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says",
    "published": 1712793000,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note",
    "published": 1712786420,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion",
    "published": 1712785620,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal",
    "published": 1712783685,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal",
    "published": 1712780373,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal",
    "published": 1712780169,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Enters Into Agreement to Acquire Alpine Immune Sciences",
    "published": 1712779260,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to buy kidney disease drugmaker Alpine for $4.9B",
    "published": 1712770440,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update",
    "published": 1712769932,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharma agrees to buy Alpine Immune Sciences for USD4.9 billion",
    "published": 1712766840,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln",
    "published": 1712765769,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Analysts\u2019 Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)",
    "published": 1712736660,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to acquire Alpine Immune Sciences for $65 per share",
    "published": 1712718120,
    "posting_price": 399.89001465,
    "close_price": 397.57998657,
    "percent_change": -0.57766586
  },
  {
    "title": "Vertex to Announce First Quarter 2024 Financial Results on May 6",
    "published": 1712693100,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?",
    "published": 1712671620,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics",
    "published": 1712671200,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Vortex Energy Gears Up for Pivotal Drilling Phase",
    "published": 1712662800,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "published": 1712658900,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project",
    "published": 1712649600,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "3 High-Growth Biotech Stocks Investors Shouldn\u2019t Sleep On in April",
    "published": 1712642760,
    "posting_price": 406.0,
    "close_price": 404.48001099,
    "percent_change": -0.37438153
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)",
    "published": 1712568660,
    "posting_price": 403.45001221,
    "close_price": 404.22000122,
    "percent_change": 0.19085116
  },
  {
    "title": "RBC says pain opinion leader 'notably negative' on Vertex's VX-548",
    "published": 1712567220,
    "posting_price": 403.45001221,
    "close_price": 404.22000122,
    "percent_change": 0.19085116
  },
  {
    "title": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
    "published": 1712288700,
    "posting_price": 404.29000854,
    "close_price": 406.67001343,
    "percent_change": 0.58868754
  },
  {
    "title": "VRTX May 24th Options Begin Trading",
    "published": 1712225220,
    "posting_price": 412.64001465,
    "close_price": 404.01000977,
    "percent_change": -2.09141251
  },
  {
    "title": "3 Underappreciated Healthcare Stocks to Buy Now: April 2024",
    "published": 1712188946,
    "posting_price": 412.64001465,
    "close_price": 404.01000977,
    "percent_change": -2.09141251
  },
  {
    "title": "Insider Sell: SVP & Chief Accounting Officer Kristen Ambrose Sells Shares of Vertex ...",
    "published": 1712185251,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Vertex Is Worth Your Attention",
    "published": 1712152802,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Truist pharmaceuticals analyst holds an analyst/industry conference call",
    "published": 1712132700,
    "posting_price": 409.45001221,
    "close_price": 408.80999756,
    "percent_change": -0.15631081
  },
  {
    "title": "Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development",
    "published": 1712071560,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease",
    "published": 1712049694,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)",
    "published": 1712039160,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)",
    "published": 1712038860,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Vertex Pharmaceuticals (VRTX) and Veeva Systems (VEEV)",
    "published": 1712032320,
    "posting_price": 419.0,
    "close_price": 409.42001343,
    "percent_change": -2.28639298
  },
  {
    "title": "Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics",
    "published": 1714483504,
    "posting_price": 396.20001221,
    "close_price": 392.80999756,
    "percent_change": -0.85563214
  },
  {
    "title": "Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?",
    "published": 1714469760,
    "posting_price": 396.20001221,
    "close_price": 392.80999756,
    "percent_change": -0.85563214
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?",
    "published": 1714399231,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "Vortex Energy Spearheads Innovative Hydrogen Storage Trial",
    "published": 1714388880,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)",
    "published": 1714380120,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "Vortex Energy\u2019s Collaboration with the University of Alberta Receives Alberta Innovates Funding",
    "published": 1714377600,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "2 Top Growth Stocks to Buy Right Now and Hold Forever",
    "published": 1714308300,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade",
    "published": 1714305840,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.",
    "published": 1714211400,
    "posting_price": 397.48001099,
    "close_price": 396.20001221,
    "percent_change": -0.32202847
  },
  {
    "title": "Pioneer Institute study finds IRA discourages non-opioid drug innovation",
    "published": 1714148558,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "Vertex Announces European Commission Approval for KALYDECO\u00ae to Treat Infants With Cystic Fibrosis Ages 1 Month and Older",
    "published": 1714146180,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals",
    "published": 1714134300,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "Interesting VRTX Put And Call Options For June 7th",
    "published": 1714130160,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "Vertex announces European Commission approval for KALYDECO",
    "published": 1714128420,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call",
    "published": 1714125780,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs",
    "published": 1714095480,
    "posting_price": 393.51998901,
    "close_price": 397.48001099,
    "percent_change": 1.00630771
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "published": 1714081819,
    "posting_price": 402.44000244,
    "close_price": 397.70001221,
    "percent_change": -1.17781289
  },
  {
    "title": "2 Fantastic Growth Stocks to Buy Right Now",
    "published": 1714052700,
    "posting_price": 402.44000244,
    "close_price": 397.70001221,
    "percent_change": -1.17781289
  },
  {
    "title": "(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest",
    "published": 1714008900,
    "posting_price": 402.44000244,
    "close_price": 397.70001221,
    "percent_change": -1.17781289
  },
  {
    "title": "Crispr Therapeutics: Now Is The Time To Buy",
    "published": 1713962409,
    "posting_price": 404.5,
    "close_price": 400.76000977,
    "percent_change": -0.92459585
  },
  {
    "title": "Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "published": 1713952200,
    "posting_price": 404.5,
    "close_price": 400.76000977,
    "percent_change": -0.92459585
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)",
    "published": 1713940260,
    "posting_price": 404.5,
    "close_price": 400.76000977,
    "percent_change": -0.92459585
  },
  {
    "title": "Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies",
    "published": 1713874140,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?",
    "published": 1713866700,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics",
    "published": 1713866351,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Vertex in-licenses cell therapy technology for diabetes candidates",
    "published": 1713860280,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis",
    "published": 1713852076,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES",
    "published": 1713847500,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Vertex Pharmaceuticals, TreeFrog Therapeutics announce licensing agreement",
    "published": 1713846840,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "Vertex obtains licence to TreeFrog's C-Stem to optimise own production",
    "published": 1713840120,
    "posting_price": 404.0,
    "close_price": 404.91000366,
    "percent_change": 0.22524843
  },
  {
    "title": "10 Best Performing Biotech ETFs in 2024",
    "published": 1713798659,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "Making Sense of Amazon CEO Andy Jassy's Latest Letter",
    "published": 1713790980,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "Buy Rating on Vertex Pharmaceuticals: Risinger\u2019s Confidence in VX-548\u2019s Billion-Dollar Potential and FDA Progress",
    "published": 1713788220,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today",
    "published": 1713784615,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now",
    "published": 1713779520,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever",
    "published": 1713620700,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "3 Relatively Safe Growth Stocks You Can Buy and Hold",
    "published": 1713610080,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "3 Biotech Stocks Set to Double by 2028",
    "published": 1713608100,
    "posting_price": 397.29998779,
    "close_price": 399.92001343,
    "percent_change": 0.65945777
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know",
    "published": 1713563418,
    "posting_price": 394.72000122,
    "close_price": 394.27999878,
    "percent_change": -0.11147204
  },
  {
    "title": "Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug",
    "published": 1713542220,
    "posting_price": 394.72000122,
    "close_price": 394.27999878,
    "percent_change": -0.11147204
  },
  {
    "title": "Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain",
    "published": 1713518611,
    "posting_price": 394.72000122,
    "close_price": 394.27999878,
    "percent_change": -0.11147204
  },
  {
    "title": "Is Vertex Pharmaceuticals Stock a Millionaire Maker?",
    "published": 1713515400,
    "posting_price": 394.72000122,
    "close_price": 394.27999878,
    "percent_change": -0.11147204
  },
  {
    "title": "CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact",
    "published": 1713508320,
    "posting_price": 394.72000122,
    "close_price": 394.27999878,
    "percent_change": -0.11147204
  },
  {
    "title": "Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?",
    "published": 1713443400,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain",
    "published": 1713441600,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)",
    "published": 1713438900,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex begins bid for US approval of non-opioid painkiller",
    "published": 1713438000,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex\u2019s stock climbs as non-opioid pain treatment advances",
    "published": 1713429480,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex starts rolling FDA submission for non-opioid pain therapy",
    "published": 1713426780,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex Pharmaceuticals announces advancements in suzetrigine pain program",
    "published": 1713425400,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition",
    "published": 1713419160,
    "posting_price": 394.19000244,
    "close_price": 393.48001099,
    "percent_change": -0.18011402
  },
  {
    "title": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "published": 1713325680,
    "posting_price": 394.94000244,
    "close_price": 393.1000061,
    "percent_change": -0.46589262
  },
  {
    "title": "Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know",
    "published": 1713304818,
    "posting_price": 396.88000488,
    "close_price": 394.17001343,
    "percent_change": -0.68282388
  },
  {
    "title": "Vortex Energy Advances Salt Project Analysis",
    "published": 1713267480,
    "posting_price": 396.88000488,
    "close_price": 394.17001343,
    "percent_change": -0.68282388
  },
  {
    "title": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today",
    "published": 1713265560,
    "posting_price": 396.88000488,
    "close_price": 394.17001343,
    "percent_change": -0.68282388
  },
  {
    "title": "Vortex Energy Corp. Sends Core Samples from the Robinsons River Salt Project to the University of Alberta",
    "published": 1713254400,
    "posting_price": 396.88000488,
    "close_price": 394.17001343,
    "percent_change": -0.68282388
  }
]